Letter: mesalazine—a safe drug with rare serious adverse events? Authors’ reply Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • LINKED CONTENTThis article is linked to Sehgal et al and Scrivo et al papers. To view these articles, visit https://doi.org/10.1111/apt.14688 and https://doi.org/10.1111/apt.15691.

publication date

  • June 2020